Intelligence · Patents
Patents expiring in 2032
Annual patent cliff calendar for 2032 — US pharmaceutical patents by expiration date.
- Patents
- 1,123
Quick answer
1,123 indexed pharmaceutical patents have expiration dates in 2032. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8183373
Solid state forms of sitagliptin salts
granted -
US 8182801
Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
granted -
US 8182835
Sustained-release liposomal anesthetic compositions
granted -
US 8182807
Method for inhibiting reperfusion injury in the brain
granted -
US 8183009
Assaying cellular markers for the evaluation of tumors
granted -
US 8183012
Methods and composition for the production of orthogonal tRNA-aminoacyltRNA synthetase pairs
granted -
US 8183338
Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof
granted -
US 8183204
Methods and compositions for increasing skin remodeling
granted -
US 8183285
Therapeutic agent for irritable bowel syndrome and methods thereof
granted -
US 8183344
Inactivation resistant factor VIII
granted -
US 8183362
Method and medicament for inhibiting the expression of a given gene
granted -
US 8183274
Treatment of hyperproliferative disorders with diarylhydantoin compounds
granted -
US 8183212
Compound having GPR54 agonistic activity
granted -
US 8183282
Therapeutic uses of urolithins
granted -
US 8183361
Oligonucleotide-containing pharmacological compositions and their use
granted -
US 8185186
Systems and methods for tissue imaging
granted -
US 8182842
Physico-chemical-managed killing of penicillin-resistant static and growing gram-positive and gram-negative vegetative bacteria
granted -
US 8182836
Abuse-resistant oral dosage forms and method of use thereof
granted -
US 8183358
Puumala virus full-length M segment-based DNA vaccines
granted -
US 8183207
Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
granted -
US 8183014
High affinity antibodies to human IL-6 receptor
granted -
US 8188095
Gyrase inhibitors and uses thereof
granted -
US 8187817
Diagnosis, treatment, and prevention of vascular disorders using IL-1 autoantibodies
granted -
US 8188061
RNAi modulation of APOB and uses thereof
granted -
US 8188221
Peptide homing to brain tumors
granted -
US 8187708
Microphasic micro-components and methods for controlling morphology via electrified jetting
granted -
US 8187874
Drug discovery method
granted -
US 8188067
Formulations of 6-mercaptopurine
granted -
US 8187591
Methods of treating coagulopathy
granted -
US 8188049
Peptides having activities of epidermal growth factor and its uses
granted -
US 8188055
Inactivators of O6-alkylguanine-DNA alkyltransferase
granted -
US 8188072
Benzodiazepinone compounds useful in the treatment of skin conditions
granted -
US 8188214
Brachyury polypeptides and methods for use
granted -
US 8187872
Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
granted -
US 8188096
Protein kinase targeted therapeutics
granted -
US 8188281
Azaindoles useful as inhibitors of JAK and other protein kinases
granted -
US 8188275
Dipeptidyl peptidase inhibitors
granted -
US 8188134
Thiophene-carboxamides useful as inhibitors of protein kinases
granted -
US 8188076
Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
granted -
US 8188132
Linked dibenzimidazole derivatives
granted -
US 8188219
Bone morphogenic protein binding peptide
granted -
US 8188071
Amino substituted pyridines as potent kinase inhibitors
granted -
US 8187606
HPV antigen fusion protein vaccine compositions and uses thereof
granted -
US 8187605
Means for the inhibition of anti-β1-adrenergic receptor antibodies
granted -
US 8188149
Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
granted -
US 8188259
Oligonucleotide-containing pharmacological compositions and their use
granted -
US 8188276
2,4-pyrimidinediamine compounds and their uses
granted -
US 8188283
Modulators of cystic fibrosis transmembrane conductance regulator
granted
Frequently asked questions
How many pharma patents expire in 2032?
1,123 published patents in our USPTO index have expiration dates falling in calendar year 2032.